Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer

Abstract Background Acquired resistance development is a major challenge in the epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR–TKI) treatment of non–small cell lung cancer (NSCLC). Here, we investigated the potential effects of the concurrent use of anlotinib and EGFR‐TKI to overco...

Full description

Bibliographic Details
Main Authors: Chen Zhang, Honggang Cao, Yanan Cui, Shidai Jin, Wen Gao, Chenjun Huang, Renhua Guo
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Thoracic Cancer
Subjects:
acquired resistance
anlotinib
EGFR‐TKI
non‐small cell lung cancer
VEGFR
Online Access:https://doi.org/10.1111/1759-7714.14141

Internet

https://doi.org/10.1111/1759-7714.14141

Similar Items